EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Auranofin is active against Histoplasma capsulatum and reduces the expression of virulence-related genes

Marcos de Abreu Almeida, Lilian Cristiane Baeza, Leandro B R Silva, Andréa Reis Bernardes-Engemann, Fernando Almeida-Silva, Rowena Alves Coelho, Iara Bastos de Andrade, Dario Corrêa-Junior, Susana Frases, Rosely Maria Zancopé-Oliveira, Alexandre Alanio, Carlos Pelleschi Taborda und 1 weitere

PLOS Neglected Tropical Diseases · 2024

DOI: 10.1371/journal.pntd.0012586 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2024. Verfasst von Marcos de Abreu Almeida und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Micologia, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Histoplasma, Auranofin, Antifungal Agents, Microbial Sensitivity Tests. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Programa Jovens Pesquisadores (INI/Fiocruz), Tripartite Fiocruz/USP/Pasteur initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Auranofin is an approved anti-rheumatic drug that has a broad-range inhibitory action against several microorganisms, including human pathogenic fungi. The auranofin activity against Histoplasma capsulatum , the dimorphic fungus that causes histoplasmosis, has not been properly addressed. Since there are few therapeutic options for this life-threatening systemic mycosis, this study evaluated the effects of auranofin on H . capsulatum growth and expression of virulence factors. Methodology/principal findings Minimal inhibitory and fungicidal concentrations (MIC and MFC, respectively) of auranofin against 15 H . capsulatum strains with distinct genetic backgrounds were determined using the yeast form of the fungus and a microdilution protocol. Auranofin activity was also assessed on a macrophage model of infection and on a Tenebrio molitor invertebrate animal model. Expression of virulence-related genes was compared between auranofin treated and untreated H . capsulatum yeast cells using a quantitative PCR assay. Auranofin affected the growth of different strains of H . capsulatum , with MIC and MFC values ranging from 1.25 to 5.0 μM and from 2.5 to >10 μM, respectively. Auranofin was able to kill intracellular H . capsulatum yeast cells and conferred protection against the fungus in the experimental animal model of infection. Moreover, the expression of catalase A, HSP70, superoxide dismutase, thioredoxin reductase, serine proteinase, cytochrome C peroxidase, histone 2B, formamidase, metallopeptidase, Y20 and YPS3 proteins were reduced after six hours of auranofin treatment. CONCLUSIONS/SIGNIFICANCE: Auranofin is fungicidal against H . capsulatum and reduces the expression of several virulence-related genes, which makes this anti-rheumatic drug a good candidate for new medicines against histoplasmosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HistoplasmaAuranofinAntifungal AgentsMicrobial Sensitivity TestsAnimalsVirulence FactorsHistoplasmosisMacrophagesMiceTenebrioVirulenceDisease Models, AnimalHumans

Substanzen

AuranofinAntifungal AgentsVirulence Factors

Autor:innen und Institutionen

  • Laboratório de Micologia, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
  • Departamento de Microbiologia e Parasitologia, Instituto Biomédico, Universidade Federal Fluminense, Niterói, Brazil.
  • Centro de Ciências Médicas e Farmacêuticas, Universidade Estadual do Oeste do Paraná, Cascavel, Brazil.
  • Departamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.
  • Department of Microbiology and Immunology, The University of British Columbia, Vancouver, Canada.
  • Laboratório de Biofísica de Fungos, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

ORCID-Profile: Rodrigo Almeida-Paes

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
  • Programa Jovens Pesquisadores (INI/Fiocruz)
  • Tripartite Fiocruz/USP/Pasteur initiative
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

Zitieren

APA

de Abreu Almeida, M., Baeza, L. C., Silva, L. B. R., Bernardes-Engemann, A. R., Almeida-Silva, F., Coelho, R. A., de Andrade, I. B., Corrêa-Junior, D., Frases, S., Zancopé-Oliveira, R. M., Alanio, A., Taborda, C. P., & Almeida-Paes, R. (2024). Auranofin is active against Histoplasma capsulatum and reduces the expression of virulence-related genes. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0012586

Vancouver

de Abreu Almeida M, Baeza LC, Silva LBR, Bernardes-Engemann AR, Almeida-Silva F, Coelho RA, et al. Auranofin is active against Histoplasma capsulatum and reduces the expression of virulence-related genes. PLOS Neglected Tropical Diseases. 2024. doi:10.1371/journal.pntd.0012586

BibTeX
@article{deAbreuAlmeida2024,
  author = {de Abreu Almeida, Marcos and Baeza, Lilian Cristiane and Silva, Leandro B R and Bernardes-Engemann, Andréa Reis and Almeida-Silva, Fernando and Coelho, Rowena Alves and de Andrade, Iara Bastos and Corrêa-Junior, Dario and Frases, Susana and Zancopé-Oliveira, Rosely Maria and Alanio, Alexandre and Taborda, Carlos Pelleschi and Almeida-Paes, Rodrigo},
  title = {Auranofin is active against Histoplasma capsulatum and reduces the expression of virulence-related genes},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2024},
  doi = {10.1371/journal.pntd.0012586}
}
Kostenlos starten →